8-KMaterial AgreementsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Nov 17, 2004)

Filed November 17, 2004For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 17, 2004, to announce a proposed amendment to its 2000 Long-Term Incentive Plan (2000 Plan). This amendment, if approved by shareholders, would introduce a one-time Option Exchange Program. This program allows eligible employees to exchange certain existing stock options for a reduced number of new options with an exercise price set at the fair market value on the grant date of the replacement options. The primary purpose of this program appears to be a form of equity compensation restructuring. By allowing employees to exchange higher-priced, potentially underwater options for new ones at current market value, the company aims to re-energize its workforce and retain key talent. The filing also notes that a preliminary proxy statement has been submitted to the SEC, outlining a special shareholder meeting to vote on this proposed amendment, emphasizing that the amendment's effectiveness is contingent on shareholder approval.

Key Highlights

  • 1Regeneron is proposing an amendment to its 2000 Long-Term Incentive Plan to create a one-time Option Exchange Program.
  • 2The program allows eligible employees to exchange certain existing stock options for new options.
  • 3Replacement options will be for a lesser number than the original options exchanged.
  • 4The exercise price of the replacement options will be set at the fair market value of the common stock on the grant date of the new options.
  • 5Shareholder approval is required for the amendment to become effective.
  • 6A preliminary proxy statement has been filed with the SEC in anticipation of a shareholder meeting to vote on the amendment.

Frequently Asked Questions

The main purpose is to allow eligible employees to exchange certain existing stock options for a lesser number of new options with a potentially more favorable exercise price (equal to the fair market value on the grant date of the new options). This is intended as a retention and motivation tool for employees holding options with exercise prices above the current market value.

Yes, shareholder approval is required. Regeneron has filed a preliminary proxy statement and will convene a special meeting of shareholders to vote on the proposed amendment to the 2000 Long-Term Incentive Plan.

If shareholders do not approve the proposed amendment at the special meeting (or any adjournment thereof), the amendment will be considered void from the beginning (void ab initio) and the Option Exchange Program will not be implemented.

This 8-K filing occurred on November 17, 2004. It signifies that Regeneron is formally proposing a significant change to its equity compensation plan, which requires shareholder consent, and is initiating the process for obtaining that consent.